Literature DB >> 11201643

Elevation of nitric oxide metabolites in the cerebrospinal fluid of patients with moyamoya disease.

A Noda1, Y Suzuki, M Takayasu, K Watanabe, T Takagi, M Hara, J Yoshida.   

Abstract

BACKGROUND: To investigate whether nitric oxide (NO) contributes to formation of abnormal collateral circulation in patients with moyamoya disease.
METHODS: Cerebrospinal fluid (CSF) samples were obtained from the subarachnoid space of the Sylvian fissure during combined bypass surgery for moyamoya disease and kept frozen until NO metabolites, nitrate and nitrite, were measured using a Griess method.
RESULTS: Compared with control CSF obtained from 18 patients with hemifacial spasm, unruptured aneurysm, etc., concentrations of NO metabolites in 26 CSF samples of 18 patients with moyamoya disease were significantly higher (mean +/- SE; 17.6 +/- 1.2 vs. 10.5 +/- 1.0 microM, p < 0.01). In eight patients, the CSF samples from both the first and second operation could be obtained. NO metabolite concentrations (20.5 +/- 2.3 microM) in CSF obtained from the first surgery decreased to 15.7 +/- 1.8 microM (p < 0.01) in CSF obtained from the second, contralateral procedure. The cases of moyamoya disease with greater development of moyamoya vessels at angiographic stage 3 and 4 tended to show higher concentrations of NO metabolites than cases at earlier or later stages with a few moyamoya vessels.
INTERPRETATION: Nitric oxide concentrations in CSF are chronically elevated in moyamoya disease, probably reflecting development of abnormal collateral circulation. i.e. moyamoya vessels. Vascular bypass surgery can reduce abnormal collateral circulation with reduced production of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11201643     DOI: 10.1007/s007010070025

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  Age-specific eNOS polymorphisms in moyamoya disease.

Authors:  Young Seok Park; Kyung Tae Min; Tae-Gon Kim; Yun Ho Lee; Hee Jin Cheong; In Sun Yeom; Joong-Uhn Choi; Dong-Seok Kim; Nam Keun Kim
Journal:  Childs Nerv Syst       Date:  2011-06-21       Impact factor: 1.475

2.  The roles of methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms in moyamoya disease patients.

Authors:  Young Seok Park; Young Joo Jeon; Hyun Seok Kim; In Bo Han; Joong-Uhn Choi; Dong-Seok Kim; Nam Keun Kim
Journal:  Childs Nerv Syst       Date:  2014-08-07       Impact factor: 1.475

Review 3.  Pathological Circulating Factors in Moyamoya Disease.

Authors:  Yao-Ching Fang; Ling-Fei Wei; Chaur-Jong Hu; Yong-Kwang Tu
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

Review 4.  The Pathophysiology of Moyamoya Disease: An Update.

Authors:  Oh Young Bang; Miki Fujimura; Seung-Ki Kim
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

5.  1H-NMR-based metabolomic analysis of cerebrospinal fluid from adult bilateral moyamoya disease: comparison with unilateral moyamoya disease and atherosclerotic stenosis.

Authors:  Jin Pyeong Jeon; Taeho Yun; Xing Jin; Won-Sang Cho; Young-Je Son; Jae Seung Bang; Hyun-Seung Kang; Chang Wan Oh; Jeong Eun Kim; Sunghyouk Park
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.